Global fibromyalgia market to double by 2015

Published on January 9, 2010 at 4:35 AM · 2 Comments

Research and Markets (http://www.researchandmarkets.com/research/72dfdc/fibromyalgia_dru) has announced the addition of GlobalData 's new report "Fibromyalgia - Drug Pipeline Analysis and Market Forecasts to 2015" to their offering.

“Fibromyalgia - Drug Pipeline Analysis and Market Forecasts to 2015”

Executive Summary:

"Fibromyalgia - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global fibromyalgia market. The report identifies the key trends shaping and driving the global fibromyalgia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global fibromyalgia sector.

The Fibromyalgia Therapeutics Market is Estimated to Grow by Roughly Double by 2015

The authors estimate the global Fibromyalgia Syndrome (FMS) market to have be worth $1 billion in 2008. It is estimated to grow at a Compound Annual Growth Rate (CAGR) of 9.2% for the next seven years to reach $1.8 billion by 2015. The growth will be driven by several factors such as escalation in FMS prevalence and the high level of unmet needs prevailing in the sector. Barriers for the FMS market are inadequate knowledge of the disease and limited effectiveness of existing drugs which moderately affect the growth of the market. The moderate treatment seeking and low diagnosis rate also act as a barrier to market volume in the sector.

The Fibromyalgia Market remains Imperceptibly Competitive

The authors analyzed the current FMS market landscape and considers it to be a weak market. The disease has recently gained the attention of the pharmaceutical sector and is gradually expected to turn into an established market. The current FMS market had only three major players including Cypress in 2009. Consequently, competition in the market is not strong. Competition in the FMS market is driven not only by product characteristics such as efficacy and safety profiles, but also by market characteristics such as the number of competitors, pricing, off-labels, and treatment flow indicators such as patient compliance and physician perceptions. Pfizer, Eli Lilly and Cypress Biosciences remain the leading competitors in the market. Together, these companies will account for approximately 85% of the global market share in 2009. Pfizer is the market leader with a share of approximately 45%. The global FMS market has a high level of unmet need compared to many other Central Nervous System (CNS) related markets.

Summary

GlobalData, the industry analysis specialist's new report, "Fibromyalgia - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global fibromyalgia market. The report identifies the key trends shaping and driving the global fibromyalgia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global fibromyalgia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Our team of industry experts.

Scope

The scope of the report includes:

  • Annualized global fibromyalgia market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
  • Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
  • Analysis of the current and future market competition in the global fibromyalgia market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with fibromyalgia.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global fibromyalgia disease market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global fibromyalgia disease market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global fibromyalgia disease market landscape? - Identify, understand and capitalize.

Key Topics Covered:

  • Executive Summary
  • 1 Overview
  • 2 Fibromyalgia Market: Market Characterization
  • 3 Fibromyalgia Market: Competitive Assessment
  • 4 Fibromyalgia Market: Pipeline Assessment
  • 5 Fibromyalgia Market: Implications for Future Market Competition
  • 6 Fibromyalgia Market: Future Players in Fibromyalgia Market
  • 7 Fibromyalgia Market: Appendix
  • List of Tables

Companies Mentioned:

  • Allergan Inc
  • GlaxoSmithKline
  • Sanofi-Aventis
  • Chelsea Therapeutics International, Ltd.
  • UCB

Posted in: Pharmaceutical News

Tags: , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
  1. Diane B. Diane B. United States says:

    Wish there was a good fibromyalgia doctor in Louisville , Ky. unfortunately my doctor asks me what would I like to try, I thought she was the doctor and I was the patient.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Research report on global pain management devices market